阿托伐他汀联合抗血小板药治疗脑梗死患者的临床疗效
|
摘要
目的探讨阿托伐他汀联合抗血小板药物(阿司匹林、氯吡格雷)治疗脑梗死患者的疗效及对血小板参数影响。方法将2016年7月至2018年6月于绥中县医院神经内科治疗的100例脑梗死患者随机分为对照组与观察组,每组50例。对照组采取抗血小板药物(阿司匹林、氯吡格雷)治疗,观察组则在对照组基础上联合阿托伐他汀治疗,比较两组患者临床疗效、病情改善时间、血小板参数改善时间、治疗前后血小板参数、不良反应发生情况。结果观察组患者临床疗效、病情改善时间、血小板参数改善时间以及治疗后血小板参数(全血黏度、血小板黏附率、血细胞比容、血浆黏度以及红细胞沉降率)均优于对照组,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论抗血小板药物(阿司匹林、氯吡格雷)联合阿托伐他汀治疗可有效改善脑梗死患者血小板参数,临床效果显著,安全性高。
Objective To explore the efficacy of atorvastatin combined with antiplatelet drugs(aspirin and clopidogrel) in the treatment of cerebral infarction and its effects on platelet parameters. Methods From July 2016 to June 2018, 100 patients with cerebral infarction treated in the Neurology Department of Suizhong County Hospital were randomly divided into control group and observation group, with 50 cases in each group. The control group was treated with antiplatelet drugs(aspirin and clopidogrel), while the observation group was treated with atorvastatin on the treatment basis of the control group. The clinical efficacy, improvement time of disease condition, improvement time of platelet parameters, platelet parameters before and after the treatment, and occurrence of adverse reactions were compared between the 2 groups. Results The clinical efficacy, the improvement time of disease condition, the improvement time of platelet parameters and the platelet parameters(whole blood viscosity, platelet adhesion rate, hematocrit, plasma viscosity and erythrocyte sedimentation rate) after the treatment of the observation group were better than those of the control group,with statistically significant difference(P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05). Conclusion Antiplatelet drugs(aspirin and clopidogrel) combined with atorvastatin can effectively improve the platelet parameters in patients with cerebral infarction. The clinical efficacy is remarkable, and the safety is high.
Objective To explore the efficacy of atorvastatin combined with antiplatelet drugs(aspirin and clopidogrel) in the treatment of cerebral infarction and its effects on platelet parameters. Methods From July 2016 to June 2018, 100 patients with cerebral infarction treated in the Neurology Department of Suizhong County Hospital were randomly divided into control group and observation group, with 50 cases in each group. The control group was treated with antiplatelet drugs(aspirin and clopidogrel), while the observation group was treated with atorvastatin on the treatment basis of the control group. The clinical efficacy, improvement time of disease condition, improvement time of platelet parameters, platelet parameters before and after the treatment, and occurrence of adverse reactions were compared between the 2 groups. Results The clinical efficacy, the improvement time of disease condition, the improvement time of platelet parameters and the platelet parameters(whole blood viscosity, platelet adhesion rate, hematocrit, plasma viscosity and erythrocyte sedimentation rate) after the treatment of the observation group were better than those of the control group,with statistically significant difference(P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05). Conclusion Antiplatelet drugs(aspirin and clopidogrel) combined with atorvastatin can effectively improve the platelet parameters in patients with cerebral infarction. The clinical efficacy is remarkable, and the safety is high.
引文
[1]袁敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对血小板参数的影响[J].医学信息,2018,31(16):123-125.
[2]中华医学会神经病学分会脑血管学组卒中诊治指南编写组.中国颅内静脉系统血栓形成诊断和治疗指南[J].中华神经科杂志,2012, 45(11):818-823.
[3]葛宝铎.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对血小板参数的影响价值体会[J].临床医药文献电子杂志,2018, 5(30):16-17.
[4]王红芹,李昊娲,孙娅楠,等.注射用丹参冻干粉针与阿司匹林抗血栓相互作用研究[J].国际中医中药杂志,2018,40(5):437-441.
[5]付阳,金亚雄,刘玉梅,等.凝血标志物在危重症血栓性疾病患者诊断中的应用及与炎性因子的相关性研究[J].中国实验血液学杂志, 2017, 25(6):1776-1780.
[6]温进坤.不要低估血管平滑肌细胞在动脉粥样硬化斑块形成中的作用[J].中国动脉硬化杂志, 2018, 26(7):649-654.
[7]王立刚,蒋天安,王颖.中青年人群右侧锁骨下动脉内膜超声检查提示早期动脉硬化的临床价值研究[J].中国超声医学杂志,2018, 34(8):680-684.
[8]盛国太,徐秀秀,葛郁芝.影响氯吡格雷药效及其代谢的相关因素[J].中国新药杂志, 2017, 26(23):2794-2798.
[9]王明跃,叶晓林.阿司匹林与替格瑞洛对急性轻型缺血性卒中溶栓后再发心脑血管风险的预防效果比较[J].实用医院临床杂志, 2018, 15(1):139-142.
[10]党冬丽,赵旭华.阿托伐他汀联合阿司匹林对脑血栓患者的疗效及血小板参数的影响[J].深圳中西医结合杂志, 2018, 28(2):32-33.
[11]韩永强,黄彦德.阿托伐他汀钙治疗颈动脉硬化的疗效观察[J].中国实用神经疾病杂志, 2017, 20(3):112-113, 114.
[12]岳新胜.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对血小板参数的影响[J].中国实用神经疾病杂志, 2017, 20(2):104-106.
[2]中华医学会神经病学分会脑血管学组卒中诊治指南编写组.中国颅内静脉系统血栓形成诊断和治疗指南[J].中华神经科杂志,2012, 45(11):818-823.
[3]葛宝铎.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对血小板参数的影响价值体会[J].临床医药文献电子杂志,2018, 5(30):16-17.
[4]王红芹,李昊娲,孙娅楠,等.注射用丹参冻干粉针与阿司匹林抗血栓相互作用研究[J].国际中医中药杂志,2018,40(5):437-441.
[5]付阳,金亚雄,刘玉梅,等.凝血标志物在危重症血栓性疾病患者诊断中的应用及与炎性因子的相关性研究[J].中国实验血液学杂志, 2017, 25(6):1776-1780.
[6]温进坤.不要低估血管平滑肌细胞在动脉粥样硬化斑块形成中的作用[J].中国动脉硬化杂志, 2018, 26(7):649-654.
[7]王立刚,蒋天安,王颖.中青年人群右侧锁骨下动脉内膜超声检查提示早期动脉硬化的临床价值研究[J].中国超声医学杂志,2018, 34(8):680-684.
[8]盛国太,徐秀秀,葛郁芝.影响氯吡格雷药效及其代谢的相关因素[J].中国新药杂志, 2017, 26(23):2794-2798.
[9]王明跃,叶晓林.阿司匹林与替格瑞洛对急性轻型缺血性卒中溶栓后再发心脑血管风险的预防效果比较[J].实用医院临床杂志, 2018, 15(1):139-142.
[10]党冬丽,赵旭华.阿托伐他汀联合阿司匹林对脑血栓患者的疗效及血小板参数的影响[J].深圳中西医结合杂志, 2018, 28(2):32-33.
[11]韩永强,黄彦德.阿托伐他汀钙治疗颈动脉硬化的疗效观察[J].中国实用神经疾病杂志, 2017, 20(3):112-113, 114.
[12]岳新胜.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对血小板参数的影响[J].中国实用神经疾病杂志, 2017, 20(2):104-106.